Tags

Type your tag names separated by a space and hit enter

Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening.
Biosensors (Basel). 2018 Jan 09; 8(1)B

Abstract

The pharmaceutical industry is facing enormous challenges due to high drug attribution rates. For the past decades, novel methods have been developed for safety and efficacy testing, as well as for improving early development stages. In vitro screening methods for drug-receptor binding are considered to be good alternatives for decreasing costs in the identification of drug candidates. However, these methods require lengthy and troublesome labeling steps. Biosensors hold great promise due to the fact that label-free detection schemes can be designed in an easy and low-cost manner. In this paper, for the first time in the literature, we aimed to compare the potential of label-free optical and impedimetric electrochemical biosensors for the screening of antipsychotic drugs (APDs) based on their binding properties to dopamine receptors. Particularly, we have chosen a currently-used atypical antipsychotic drug (Buspirone) for investigating its dopamine D3 receptor (D3R) binding properties using an impedimetric biosensor and a nanoplasmonic biosensor. Both biosensors have been specifically functionalized and characterized for achieving a highly-sensitive and reliable analysis of drug-D3R binding. Our biosensor strategies allow for comparing different affinities against the D3R, which facilitates the identification of strong or weak dopamine antagonists via in vitro assays. This work demonstrates the unique potential of label-free biosensors for the implementation of cost-efficient and simpler analytical tools for the screening of antipsychotic drugs.

Authors+Show Affiliations

Integrated Systems Laboratory (LSI), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland. tugba.kilic@epfl.ch.Bionanophotonic Systems Laboratory (BIOS), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland. maria.soleraznar@epfl.ch.Bionanophotonic Systems Laboratory (BIOS), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland. Department of Chemistry, Sharif University of Technology, Tehran 11155-9516, Iran.Bionanophotonic Systems Laboratory (BIOS), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland. hatice.altug@epfl.ch.Integrated Systems Laboratory (LSI), Swiss Federal Institute of Technology Lausanne, EPFL, CH-1015 Lausanne, Switzerland. sandro.carrara@epfl.ch.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29315269

Citation

Kilic, Tugba, et al. "Mining the Potential of Label-Free Biosensors for in Vitro Antipsychotic Drug Screening." Biosensors, vol. 8, no. 1, 2018.
Kilic T, Soler M, Fahimi-Kashani N, et al. Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening. Biosensors (Basel). 2018;8(1).
Kilic, T., Soler, M., Fahimi-Kashani, N., Altug, H., & Carrara, S. (2018). Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening. Biosensors, 8(1). https://doi.org/10.3390/bios8010006
Kilic T, et al. Mining the Potential of Label-Free Biosensors for in Vitro Antipsychotic Drug Screening. Biosensors (Basel). 2018 Jan 9;8(1) PubMed PMID: 29315269.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening. AU - Kilic,Tugba, AU - Soler,Maria, AU - Fahimi-Kashani,Nafiseh, AU - Altug,Hatice, AU - Carrara,Sandro, Y1 - 2018/01/09/ PY - 2017/11/30/received PY - 2017/12/22/revised PY - 2018/01/08/accepted PY - 2018/1/10/entrez PY - 2018/1/10/pubmed PY - 2018/9/7/medline KW - dopamine receptor KW - drug screening KW - electrochemical biosensor KW - label-free detection KW - nanoplasmonic biosensor JF - Biosensors JO - Biosensors (Basel) VL - 8 IS - 1 N2 - The pharmaceutical industry is facing enormous challenges due to high drug attribution rates. For the past decades, novel methods have been developed for safety and efficacy testing, as well as for improving early development stages. In vitro screening methods for drug-receptor binding are considered to be good alternatives for decreasing costs in the identification of drug candidates. However, these methods require lengthy and troublesome labeling steps. Biosensors hold great promise due to the fact that label-free detection schemes can be designed in an easy and low-cost manner. In this paper, for the first time in the literature, we aimed to compare the potential of label-free optical and impedimetric electrochemical biosensors for the screening of antipsychotic drugs (APDs) based on their binding properties to dopamine receptors. Particularly, we have chosen a currently-used atypical antipsychotic drug (Buspirone) for investigating its dopamine D3 receptor (D3R) binding properties using an impedimetric biosensor and a nanoplasmonic biosensor. Both biosensors have been specifically functionalized and characterized for achieving a highly-sensitive and reliable analysis of drug-D3R binding. Our biosensor strategies allow for comparing different affinities against the D3R, which facilitates the identification of strong or weak dopamine antagonists via in vitro assays. This work demonstrates the unique potential of label-free biosensors for the implementation of cost-efficient and simpler analytical tools for the screening of antipsychotic drugs. SN - 2079-6374 UR - https://www.unboundmedicine.com/medline/citation/29315269/Mining_the_Potential_of_Label_Free_Biosensors_for_In_Vitro_Antipsychotic_Drug_Screening_ L2 - http://www.mdpi.com/resolver?pii=bios8010006 DB - PRIME DP - Unbound Medicine ER -